Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 1 Evolution of MRI findings during interleukin (IL)–7 therapy

Published byMüge Necmi Modified over 5 years ago

Similar presentations

Presentation on theme: "Figure 1 Evolution of MRI findings during interleukin (IL)–7 therapy"— Presentation transcript:

1 Figure 1 Evolution of MRI findings during interleukin (IL)–7 therapy
Evolution of MRI findings during interleukin (IL)–7 therapy Axial fluid-attenuated inversion recovery images from (A, B) pre-IL-7 and (C, D) 2 weeks post-IL-7 MRI of the brain demonstrate stable left hemispheric subcortical progressive multifocal leukoencephalopathy (PML) lesions, but a new, small, asymptomatic left cerebellar lesion (white arrow), (E, F) which remains unchanged on the most recent MRI performed 16 weeks after IL-7 therapy. Dhanashri P. Miskin et al. Neurol Neuroimmunol Neuroinflamm 2016;3:e213 © 2016 American Academy of Neurology

Download ppt "Figure 1 Evolution of MRI findings during interleukin (IL)–7 therapy"

Similar presentations

1 Copyright © 2014 Elsevier Inc. All rights reserved. Chapter 43 Nervous System Complications of Systemic Viral Infections John E. Greenlee.

1 Copyright © 2014 Elsevier Inc. All rights reserved. Chapter 43 Nervous System Complications of Systemic Viral Infections John E. Greenlee.
Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol
Figure 2. A patient with multifocal nodular lesions diagnosed with CNS tuberculosis A patient with multifocal nodular lesions diagnosed with CNS tuberculosis.

Figure 2. A patient with multifocal nodular lesions diagnosed with CNS tuberculosis A patient with multifocal nodular lesions diagnosed with CNS tuberculosis.
Figure 2. MRI features of patients with MS who had antibodies to myelin oligodendrocyte glycoprotein MRI features of patients with MS who had antibodies.

Figure 2. MRI features of patients with MS who had antibodies to myelin oligodendrocyte glycoprotein MRI features of patients with MS who had antibodies.
Figure 1 Initial brain imaging (A–C) patient 1; (D–F) patient 2; (G–I) patient 3; (J–L) patient 4; and (M) patient 2. Initial brain imaging (A–C) patient.

Figure 1 Initial brain imaging (A–C) patient 1; (D–F) patient 2; (G–I) patient 3; (J–L) patient 4; and (M) patient 2. Initial brain imaging (A–C) patient.
Figure 3 Brain MRI findings in patients with MOG-Ab Extensive brain lesions with large diameter (A and B), posterior reversible encephalopathy–like lesions.

Figure 3 Brain MRI findings in patients with MOG-Ab Extensive brain lesions with large diameter (A and B), posterior reversible encephalopathy–like lesions.
Figure 4 Neuromyelitis optica spectrum disorder brain lesions

Figure 4 Neuromyelitis optica spectrum disorder brain lesions
Figure 1 Brain MRI findings in the present case

Figure 1 Brain MRI findings in the present case
Figure 4. Brain imaging and neuropathologic demonstration of Epstein-Barr virus (EBV) encephalitis in patient PT-10 Brain imaging and neuropathologic demonstration.

Figure 4. Brain imaging and neuropathologic demonstration of Epstein-Barr virus (EBV) encephalitis in patient PT-10 Brain imaging and neuropathologic demonstration.
Figure 2 Evolution of MRI abnormalities in faciobrachial dystonic seizures Axial fluid- attenuated inversion recovery (FLAIR)-weighted images from patient.

Figure 2 Evolution of MRI abnormalities in faciobrachial dystonic seizures Axial fluid- attenuated inversion recovery (FLAIR)-weighted images from patient.
Figure 2 Association of serum IgG reactivity with MRI measures of disease severity Association of serum IgG reactivity with MRI measures of disease severity.

Figure 2 Association of serum IgG reactivity with MRI measures of disease severity Association of serum IgG reactivity with MRI measures of disease severity.
Figure 2 Spinal cord lesions

Figure 2 Spinal cord lesions
Figure 1 Coronal MRI images showing the evolution of white matter abnormality and atrophy of patient 1 Coronal MRI images showing the evolution of white.

Figure 1 Coronal MRI images showing the evolution of white matter abnormality and atrophy of patient 1 Coronal MRI images showing the evolution of white.
Figure Facial photograph during headache attack and brain and upper cervical cord MRI Facial photograph during headache attack and brain and upper cervical.

Figure Facial photograph during headache attack and brain and upper cervical cord MRI Facial photograph during headache attack and brain and upper cervical.
Figure Brain MRI of the patient throughout the disease course(A) Brain MRI at the time of cerebral toxoplasmosis diagnosis (a) and after 1 month of toxoplasmosis.

Figure Brain MRI of the patient throughout the disease course(A) Brain MRI at the time of cerebral toxoplasmosis diagnosis (a) and after 1 month of toxoplasmosis.
Figure 3 Example of venous narrowing

Figure 3 Example of venous narrowing
Figure Patient 1's ictal EEG and brain MRI and patient 2's ictal EEG and polygraphic recording(A) Patient 1's EEG showing an ictal discharge over right.

Figure Patient 1's ictal EEG and brain MRI and patient 2's ictal EEG and polygraphic recording(A) Patient 1's EEG showing an ictal discharge over right.
Figure 1 MRI head in faciobrachial dystonic seizures (A) Axial fluid-attenuated inversion recovery image from patient 3 in table 2 shows T2-weighted hyperintensity.

Figure 1 MRI head in faciobrachial dystonic seizures (A) Axial fluid-attenuated inversion recovery image from patient 3 in table 2 shows T2-weighted hyperintensity.
Figure Radiographic and histopathologic findings (A) Brain MRI at presentation shows multiple areas of T2 hyperintensity in the mesial temporal lobes,

Figure Radiographic and histopathologic findings (A) Brain MRI at presentation shows multiple areas of T2 hyperintensity in the mesial temporal lobes,
Figure 1. Prebiopsy and postbiopsy MRI

Figure 1. Prebiopsy and postbiopsy MRI

Similar presentations

Ads by Google